Clinical Trial Update: Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab [Phase 4]

View source ↗

Summary

A phase 4 clinical trial evaluating intravitreal aflibercept for center-involved diabetic macular edema previously managed with ranibizumab has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• EYLEA (Aflibercept)
• Lucentis (ranibizumab)

Snippet

Sponsor: Southeast Clinical Research Associates, LLC | Conditions: Diabetic Macular Edema | Phase 4 | Status: WITHDRAWN